Guillain–Barré syndrome following COVID‐19 vaccine: A case report
Open Access
- 13 October 2022
- journal article
- research article
- Published by Wiley in Clinical Case Reports
- Vol. 10 (10) , e6451
Abstract
Coronavirus disease is a viral infection affecting different organs with various morbidities and mortality. Vaccines are used to control the disease. COVID‐19 vaccines have brought many benefits but their adverse effects should not be ignored. Here, we report a case of Guillain–Barré Syndrome Following Sinopharm COVID‐19 Vaccine.Keywords
All Related Versions
This publication has 13 references indexed in Scilit:
- Guillain-Barré syndrome after AstraZeneca COVID-19-vaccination: A causal or casual association?Clinical Neurology and Neurosurgery, 2021
- Effects of different types of written vaccination information on COVID-19 vaccine hesitancy in the UK (OCEANS-III): a single-blind, parallel-group, randomised controlled trialThe Lancet Public Health, 2021
- COVID-19 vaccines: modes of immune activation and future challengesNature Reviews Immunology, 2021
- COVID-19: Coronavirus Vaccine Development UpdatesFrontiers in Immunology, 2020
- Guillain-Barré syndrome in SARS-CoV-2 infection: an instant systematic review of the first six months of pandemicJournal of Neurology, Neurosurgery & Psychiatry, 2020
- Effect of an Inactivated Vaccine Against SARS-CoV-2 on Safety and Immunogenicity OutcomesJAMA, 2020
- Clinical Features of Post-Vaccination Guillain-Barré Syndrome (GBS) in KoreaJournal of Korean Medical Science, 2017
- Guillain-Barré syndromeThe Lancet, 2016
- Diagnosis of Guillain-Barre syndrome and validation of Brighton criteriaBrain, 2013
- Clinical and Epidemiologic Features of Guillain‐Barré SyndromeThe Journal of Infectious Diseases, 1997